<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="2046" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="734" end="744"/>
    <type:ORR xmi:id="17" sofa="6" begin="833" end="837"/>
    <type:ORR xmi:id="21" sofa="6" begin="845" end="849"/>
    <type:OSMean xmi:id="25" sofa="6" begin="872" end="875"/>
    <type:OSMean xmi:id="29" sofa="6" begin="883" end="893"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: To compare vinflunine (VFL) to docetaxel in patients with stage IIIB/IV &#13;&#10;non-small-cell lung cancer (NSCLC) who have experienced treatment failure with&#13;&#10;first-line platinum-based chemotherapy.&#13;&#10;PATIENTS AND METHODS: Randomized, multicenter, phase III study, 551 patients&#13;&#10;received either vinflunine 320 mg/m(2) or docetaxel 75 mg/m(2) every 21 days&#13;&#10;until disease progression or serious toxicity. The primary end point was&#13;&#10;progression-free survival (PFS). The noninferiority analysis was based on a 10%&#13;&#10;difference (types I/II error rates: 5%/20%). Secondary end points included&#13;&#10;response rate (ORR), response duration, overall survival (OS), clinical benefit, &#13;&#10;quality of life (QOL), and safety.&#13;&#10;RESULTS: Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to&#13;&#10;1.199). ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus&#13;&#10;39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.&#13;&#10;No significant difference in patient benefit and QOL (Functional Assessment of&#13;&#10;Cancer Therapy-Lung). No unexpected adverse events were observed. Grade higher&#13;&#10;than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v&#13;&#10;39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%),&#13;&#10;constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction&#13;&#10;(31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8%&#13;&#10;v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7%&#13;&#10;v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%),&#13;&#10;diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%)&#13;&#10;were observed.&#13;&#10;CONCLUSION: This noninferiority phase III study showed similar efficacy end&#13;&#10;points for vinflunine and docetaxel. Despite higher rates of some adverse effects&#13;&#10;(anemia, abdominal pain, constipation, fatigue) the overall toxicity profile of&#13;&#10;vinflunine was manageable. Therefore, VFL may be another option in the&#13;&#10;second-line treatment of patients with advanced NSCLC."/>
    <cas:View sofa="6" members="1 13 17 21 25 29"/>
</xmi:XMI>
